# A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

> **NCT07740486** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Polish Myeloma Consortium** · enrollment: 248 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** Teclistamab
- **DRUG:** Talquetamab
- **DRUG:** Daratumumab (Subcutaneously)
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT07740486
- **Lead sponsor:** Polish Myeloma Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2031-06
- **Final completion:** 2033-04
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2026-07-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07740486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07740486, "A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07740486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*